glp 1 non responders glp-1 responder to Agonists and the Non-Responder Problem: What We Know, What We Assume, and What Why Some Patients Do Not – The promise and peril of – glp 1 non responders Not

Hyperkalemia Drugs That Cause Hypokalemia (Low Potassium) These drugs increase potassium loss from the kidneys or shift potassium into cells: Diuretics (most common cause): Loop diuretics: Furosemide, Torsemide Thiazide diuretics: Hydrochlorothiazide, Chlorthalidone Corticosteroids: Prednisolone, Dexamethasone (mineralocorticoid effect) Beta-2 Agonists: Salbutamol (Albuterol), Terbutaline Insulin (in high doses): Drives potassium into cells Amphotericin B High-dose Penicillins (e.g., Carbenicillin, Piperacillin) act as non-reabsorbable anions Theophylline Laxative abuse / diarrhea-causing drugs Clinical signs: Muscle weakness, cramps, arrhythmias (e.g., U-waves on ECG) Drugs That Cause Hyperkalemia (High Potassium) These drugs reduce potassium excretion or increase potassium retention: Potassium-sparing diuretics: Spironolactone, Eplerenone (Aldosterone antagonists) Amiloride, Triamterene ACE Inhibitors: Enalapril, Ramipril, Lisinopril ARBs: Losartan, Telmisartan, Valsartan Direct Renin Inhibitor: Aliskiren NSAIDs: Indomethacin, Ibuprofen (reduce renal perfusion) Heparin (including low molecular weight) Trimethoprim Beta-blockers (especially non-selective): Propranolol Digoxin (in toxicity) Cyclosporine, Tacrolimus Clinical signs: Peaked T-waves, muscle weakness, risk of cardiac arrest Key Tip for Memory | Potassium (Hypo) Think Diuretics & -Agonists | Potassium (Hyper) Think RAAS Blockers & K-Sparing Drugs | To view or add a comment, sign in WHY NASAL DELIVERY OF GLP-1 PEPTIDES? In contrast to the oral and subcutaneous routes of administration, nasal delivery of GLP-1 peptide drugs provides unique advantages: The nasal mucosal environment is less acidic, less digestive, and simpler to use than the oral delivery route

If your skin makes too few or too many AMPs, you may have psoriasis, eczema, rosacea, or acne

Having more control over the pace and dose could help mitigate potential side effects associated with the medication at therapeutic doses, such as nausea, diarrhea and constipation

GLP-1R agonists (GLP-1RAs) function through activating GLP-1R and are primarily used in the treatment of type 2 diabetes (T2D) and obesity

10.1080/152165400410281 IUBMB Life